New Safety Research Sheds Light on Crucial Child Safety Product Concerns
BREDARYD, SWEDEN, Sept 28, 2023 – (ACN Newswire) – In a dedicated effort to enhance…
BREDARYD, SWEDEN, Sept 28, 2023 – (ACN Newswire) – In a dedicated effort to enhance…
Toronto, Ontario–(ACN Newswire – September 28, 2023) – Appia Rare Earths & Uranium Corp. (CSE: API)…
Recognized for its Innovative AI Solutions for Insurance Underwriting and Claims Management BOSTON–(BUSINESS WIRE)–#AIinInsurance—Gradient AI,…
Contract will support continued development of Sarcos artificial intelligence and machine learning framework to advance…
Providing investors a differentiated income strategy which couples high income potential with long term growth…
Students enter by submitting a video about the future of AI in real estate LOS…
SOUTH SAN FRANCISCO, Calif., Sept. 28, 2023 (GLOBE NEWSWIRE) — Epic Bio, a biotechnology company…
SOUTH SAN FRANCISCO, Calif., Sept. 28, 2023 (GLOBE NEWSWIRE) — Epic Bio, a biotechnology company…
INPEFA® (sotagliflozin) recently approved by FDA for treatment of heart failure SCORED was one of…
INPEFA® (sotagliflozin) recently approved by FDA for treatment of heart failure SCORED was one of…
NEW YORK, Sept. 28, 2023 (GLOBE NEWSWIRE) — Nusano, Inc., a company reshaping the production…
NEW YORK, Sept. 28, 2023 (GLOBE NEWSWIRE) — Nusano, Inc., a company reshaping the production…
Revolutionary Cleaner Utilizes Organic Waste to Safely and Effectively Remove Algae from Outdoor Surfaces Green…
Revolutionary Cleaner Utilizes Organic Waste to Safely and Effectively Remove Algae from Outdoor Surfaces Green…
Trial participants with Spastic Paraplegia 50 (SPG50) and Charcot-Marie-Tooth disease type 4J (CMT4J) could benefit…
Trial participants with Spastic Paraplegia 50 (SPG50) and Charcot-Marie-Tooth disease type 4J (CMT4J) could benefit…
The FDA and Health Canada have cleared the initiation of the expansion portion of COVALENT-111,…
The FDA and Health Canada have cleared the initiation of the expansion portion of COVALENT-111,…
Intent-to-treat population shows 9-month OS improvement over control arm Subgroup of patients treated with IMNN-001…
Intent-to-treat population shows 9-month OS improvement over control arm Subgroup of patients treated with IMNN-001…